Jeffrey C. Gildersleeve, Ph.D.
- Center for Cancer Research
- National Cancer Institute
- Building 376, Room 208
- Frederick, MD 21702-1201
The Gildersleeve group develops unique technologies and tools to research important but under studied problems at the intersection of cancer immunology and glycoscience. We use a variety of chemical and biological approaches to (1) understand how the immune system constructs glycan-binding antibodies, (2) investigate how endogenous glycan-binding antibodies contribute to human health, (3) develop new strategies to obtain and engineer glycan-binding antibodies with high affinity and selectivity, and (4) apply monoclonal antibodies to study glycobiology, especially as it relates to cancer. To facilitate these studies, we have a developed a glycan microarray, or carbohydrate antigen microarray, that allows high-throughput analysis of antibody binding properties and rapid profiling of glycan-binding antibody populations in serum.
Areas of Expertise
The goal of our group is to understand how antibodies to carbohydrates are generated, what they do, and how we can use them to improve cancer care. We focus in two main areas: 1) developing and studying carbohydrate binding monoclonal antibodies, and 2) understanding the roles of serum anti-glycan antibodies for cancer treatment, especially immunotherapies. To facilitate these studies, we have developed a carbohydrate microarray, or glycan array, that allows high-throughput analysis of antibody binding properties and profiling of serum anti-glycan antibody populations. The array has over 800 array components, including a diverse collection of glycans, glycopeptides, and natural glycoproteins. Our array is unique in that we use multivalent neoglycoproteins as our primary array components. This format allows us to readily translate array results to other applications and affords novel approaches to vary glycan presentation.
Monoclonal Antibodies to Carbohydrates
Anti-glycan antibodies have significant potential for cancer applications such as diagnostics and therapeutics. Unfortunately, there are relatively few good carbohydrate binding antibodies available for the community. The lack of antibodies is a major problem for basic research in the field of glycobiology and limits antibody-based diagnostics and therapeutics. We have been taking a multipronged approach to improving access to carbohydrate binding antibodies. We study how the immune system constructs and evolves glycan binding antibodies, develop new strategies for engineering glycan-binding antibodies, and study basic principles of antibody-carbohydrate recognition. We also use our microarray to obtain new monoclonal antibodies with high affinity and selectivity for a variety of applications. Lastly, we have developed a database of glycan binding antibodies and reagent lectins, called Database of Anti-Glycan Reagents or DAGR, https://ccr2.cancer.gov/resources/Cbl/Tools/Antibody/). DAGR provides a unique resource where researchers can locate antibodies of interest and find information about those antibodies.
Antibody Responses to Vaccines and Other Immunotherapies
We have a long-standing interest in understanding the roles of anti-glycan serum antibodies in the treatment of cancer. We are especially interested in studying antibody responses induced by cancer vaccines and other immunotherapies. We have evaluated responses by whole cell vaccines (e.g.GVAX Pancreas), poxvirus-based vaccines (e.g. PROSTVAC), and carbohydrate-based cancer vaccines. These projects are shedding new light on how cancer vaccines and other immunotherapies work and are uncovering new biomarkers for precision medicine.
Glycan microarray technology
We rely heavily on glycan array technology to study immune responses to carbohydrates, and we continually strive to improve this technology. First, carbohydrate-protein interactions often involve formation of multivalent complexes. Therefore, presentation is a key feature of recognition. We have developed several new approaches to vary carbohydrate presentation on the surface of the array, including methods to vary glycan density and neoglycoprotein density. Second, we use synthetic organic chemistry to obtain a diverse set of tumor-associated carbohydrates and glycopeptides to populate our array.
Collaborations and Carbohydrate Microarray Screening
We are frequently asked to screen lectins, antibodies, and other entities on our array. Although we are not a core facility and do not provide screening services per se, we are happy to collaborate on many projects, especially those related to cancer. Please contact Jeff Gildersleeve for more details.
The Database of Anti-Glycan Reagents (DAGR) is a community resource to help researchers identify carbohydrate-binding antibodies and lectins. The DAGR website can be used to search for antibodies and lectins, find information about antibodies/lectins, and add new antibodies/lectins to the database.
The Database of Anti-Glycan Reagents can be found at the following link:
Development of a GalNAc-Tyrosine-Specific Monoclonal Antibody and Detection of Tyrosine O-GalNAcylation in Numerous Human Tissues and Cell Lines
Selective Recognition of Carbohydrate Antigens by Germline Antibodies Isolated from AID Knockout Mice
Chemoenzymatic Synthesis of 9NHAc-GD2 Antigen to Overcome the Hydrolytic Instability of O-Acetylated-GD2 for Anticancer Conjugate Vaccine Development
Jeffrey C. Gildersleeve, Ph.D.
Jeff Gildersleeve obtained his B.S. degree in biology from the University of California at San Diego. He obtained his Ph.D. degree in organic chemistry at Princeton University under the guidance of Professor Dan Kahne, and completed postdoctoral training with Professor Peter Schultz at The Scripps Research Institute. He began his independent career at the National Cancer Institute in 2003 and is currently a Senior Investigator in the Chemical Biology Laboratory. The Gildersleeve group uses chemical approaches and glycan microarray technology to design and develop new carbohydrate-binding antibodies as research tools, diagnostics, and therapeutics. Dr. Gildersleeve is a recipient of the 2006 NCI Director’s Innovation Award and the 2011 David Y. Gin New Investigator Award from the Division of Carbohydrate Chemistry of the American Chemical Society. He also serves on the Scientific Advisory Board of the Canadian Glycomics Network, as a reviewer for various grant agencies and journals, and on Faculty Opinions (Faculty of 1000).
There are no open positions at this time. Check back again later, or take a look at CCR's Careers page.
Learn more about CCR research advances, new discoveries and more on our news section.